Comparing Heyu Biological Technology (OTCMKTS:HYBT) & NeurAxis (NASDAQ:NRXS)

Heyu Biological Technology (OTCMKTS:HYBT) and NeurAxis (NASDAQ:NRXS) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Valuation and Earnings

This table compares Heyu Biological Technology and NeurAxis’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heyu Biological Technology	$80,000.00	322.65	-$270,000.00	N/A	N/A
NeurAxis	$2.27 million	9.33	-$14.63 million	($3.73)	-0.85

Heyu Biological Technology has higher earnings, but lower revenue than NeurAxis.

Profitability

This table compares Heyu Biological Technology and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heyu Biological Technology	-453.55%	-6.43%	-4.43%
NeurAxis	-633.10%	N/A	-926.02%

Analyst Ratings

This is a summary of current ratings for Heyu Biological Technology and NeurAxis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heyu Biological Technology	0	0	0	0	N/A
NeurAxis	0	0	1	0	3.00

Insider and Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. 89.2% of Heyu Biological Technology shares are owned by insiders. Comparatively, 15.2% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Heyu Biological Technology beats NeurAxis on 5 of the 9 factors compared between the two stocks.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.